Pemphigus vulgaris

SinoMab Received the Highest Subsidy from HKSTP

Retrieved on: 
星期五, 七月 8, 2022
Patient, Heart, Research, Pemphigus vulgaris, NMOSD, Investigational New Drug, Hong Kong Science and Technology Parks Corporation, Growth, Company, Industry, Innovation and Technology Bureau, Mab, IND, Neuromyelitis optica spectrum disorder, National Medical Products Administration, Thirteenth, Twelfth, PV, Therapy, Science park, NMPA, CD22, The Company, RA, B-cell lymphoma, MS, Biotechnology, Electronics, Technology, SLE, ITR, Lupus, Multiple sclerosis, Ecosystem, I&T, Translational research, GBA, CTC, Center for Drug Evaluation and Research, Rheumatoid arthritis, CDE, Trial of the century, SM03, HKSAR, R, BTK, The Group, NHL, Safety, Asthma, HKSTP, Center, Program, Hong Kong Science Park, Pharmaceutical industry, Guangdong-Hong Kong-Macau Greater Bay Area

Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.

Key Points: 
  • Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.
  • SinoMab stood out from many biopharmaceutical companies in the CTC program and was granted the highest subsidy amount, embodying the recognition by the evaluation committee on the Company's product candidates and research and development (R&D) plan.
  • Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "By launching the CTC program, HKSTP provides great support to local biopharmaceutical companies on their New Drug R&D.
  • With the smooth progress of clinical trials of the Company's key candidates, the subsidy from the HKSTP will provide a solid foundation for the Company's continuous R&D and stepping toward commercialization.

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

Retrieved on: 
星期三, 六月 15, 2022
Organic, Industry, T helper cell, FDA, Food and Drug Administration, Therapy, Health, FIC, Safety, State, The Company, NHL, RA, CD22, SM03, Pemphigus vulgaris, Company, Coronavirus Scientific Advisory Board (Turkey), Asthma, Pharmacokinetics, Innate lymphoid cell, Research, B-cell lymphoma, Disease, Investigational New Drug, Rheumatoid arthritis, Mab, FRS, Molecular biology, MRC Laboratory of Molecular Biology, IND, Quality of life, SAD, Lupus, LifeArc, Single, Thirteenth, SLE, Food, Patient, Francis Crick Institute, United Kingdom, PV, MAD, Twelfth, LMB, The Group, Risk, Pharmaceutical industry, ILC2

SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).

Key Points: 
  • SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).
  • Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial.
  • After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients.
  • Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
星期四, 六月 9, 2022
The Company, National Medical Products Administration, Degenerative disease, CDE, Company, Neuromyelitis optica spectrum disorder, Pemphigus vulgaris, Lupus, Research, NHL, Mab, Drug discovery, Safety, CD22, Epstein–Barr virus infection, SM03, RA, SLE, Central nervous system, Optic neuritis, Disease, Smoking, Center, Investigational New Drug, IND, Therapy, Optic nerve, NMPA, Spinal cord, Twelfth, PV, Thirteenth, Patient, MS, BTK, Rheumatoid arthritis, Incidence, Antibody, Union, IL-6, Multiple sclerosis, US, The Group, Center for Drug Evaluation and Research, EBV, Asthma, NMOSD, B-cell lymphoma, Recurrence, Pharmaceutical industry, Pemphigus, Phase

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety.
  • An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China.

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Retrieved on: 
星期四, 五月 19, 2022
Degenerative disease, Risk, No, Company, Pemphigus foliaceus, Annual general meeting, Neuromuscular Disorders, Immunoglobulin G, PV, Pemphigus vulgaris, Infection, Euronext, Patient, Biology, SID, Antibody, Quality of life, BP, Research, Journal of the American Academy of Dermatology, FC, Instagram, IIP, Breda, Neutrophil, Lymphocyte, Monocyte, Skin, LinkedIn, Twitter, Recurrent corneal erosion, Society, Acantholysis, Red blood cell, Pharmaceutical industry, Vaccine, Cell, Neonatal Fc receptor, Dermatology, Pemphigus, Pemphigus

The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.

Key Points: 
  • The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.
  • Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

Retrieved on: 
星期三, 四月 20, 2022
Pemphigus vulgaris, BTK, SM03, Investigational New Drug, Twelfth, IND, Multiple sclerosis, RA, Spinal cord, CD22, B-cell lymphoma, Asthma, NMPA, Ibrutinib, Research, NHL, The Group, Lupus, Pemphigus, Brain, CAGR, Patient, MS Research Australia, Demyelinating disease, The Company, Rheumatoid arthritis, Company, US, Degenerative disease, Movement disorders, SLE, Safety, Mab, National Medical Products Administration, Prevalence, MS, Thirteenth, Therapy, PV, Drug discovery, Pharmaceutical industry, Phase

The IND approval would enable the Company to initiate the Phase II clinical study to evaluate the efficacy and safety of SN1011 in patients with multiple sclerosis in China.

Key Points: 
  • The IND approval would enable the Company to initiate the Phase II clinical study to evaluate the efficacy and safety of SN1011 in patients with multiple sclerosis in China.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • Currently, the IND application for SN1011 in the treatment of systemic lupus erythematosus (SLE), pemphigus vulgaris (PV) and multiple sclerosis (MS) have been approved by NMPA, the Company plans to launch the Phase II clinical study for pemphigus in the third quarter of 2022.
  • The approval of this IND application is the third indication of SN1011 in China following the approval of IND application for SLE and pemphigus, fully demonstrating the great potential of our innovative BTK inhibitor in the field of the treatment of autoimmune diseases.

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

Retrieved on: 
星期一, 三月 14, 2022
Safety, United Kingdom, Asthma, FIH, Patient, Risk, Rheumatoid arthritis, Company, IND, Research, Lupus, Therapy, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LifeArc, Allergy, Quality of life, Pemphigus vulgaris, Idiopathic pulmonary fibrosis, Investigational New Drug, The Company, Mab, Humanized antibody, Twelfth, CD22, RA, Lincoln Hospital (Bronx), T helper cell, NHL, Thirteenth, FIC, B-cell lymphoma, The Group, PV, Food, SLE, SM03, Health, Pharmaceutical industry, PRC

The IND approval would enable the Company to initiate the First-In-Human (FIH) study in the U.S. in the first quarter of 2022 at the earliest.

Key Points: 
  • The IND approval would enable the Company to initiate the First-In-Human (FIH) study in the U.S. in the first quarter of 2022 at the earliest.
  • Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.
  • Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbation rates to a certain extent.
  • The Company believes the huge potential of SM17 to satisfy unmet medical needs in asthma treatment.

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

Retrieved on: 
星期四, 二月 17, 2022
United Kingdom, Asthma, Twelfth, Patient, Food, Mortality, The Group, Company, The Company, Allergy, PV, NHL, Idiopathic pulmonary fibrosis, LifeArc, Mab, IND, NMPA, Safety, T helper cell, Drug resistance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Rheumatoid arthritis, Cytokine, FIC, Humanized antibody, SLE, Drug discovery, US, SM03, CD22, Investigational New Drug, RA, FDA, Pemphigus vulgaris, R gene, Research, Thirteenth, Lupus, B-cell lymphoma, Drug development, EST, Sclerosis, Pharmaceutical industry, PRC

The Company plans to initiate the First-In-Human study in the U.S. in first quarter of 2022, once IND is approved by FDA.

Key Points: 
  • The Company plans to initiate the First-In-Human study in the U.S. in first quarter of 2022, once IND is approved by FDA.
  • SM17 is the world's first monoclonal antibodies targeting IL17BR co-developed by SinoMab and LifeArc (a medical research charity based in the United Kingdom).
  • SM17 has a wide range of indications, including indications with large market volumes such as asthma and diseases with high mortality rates such as idiopathic pulmonary fibrosis.
  • With the preclinical data and unique mechanism of action of SM17, Company believes that SM17 potentially has a broader and more beneficial effect on asthma treatment than other approved biologics.

DGAP-News: Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

Retrieved on: 
星期二, 二月 15, 2022
Roche, Patient, Allergy, IL-6, Novimmune, Company, TPM, Life cycle, Rheumatology, Rheumatoid arthritis, Type 1 diabetes, Therapy, Degenerative disease, Medical director, Drug development, Pharmaceutical industry, Topas, Pemphigus vulgaris

Topas Therapeutics Appoints Cristina de Min, M.D.

Key Points: 
  • Topas Therapeutics Appoints Cristina de Min, M.D.
  • as Chief Medical Officer
    She will drive the advancement of Topas' development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease
    Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced the appointment of Cristina de Min, M.D., as Chief Medical Officer.
  • Klaus Martin, Ph.D., Chief Executive Officer, said: "I am thrilled to welcome Cristina to Topas.
  • Cristina de Min, M.D., Chief Medical Officer, said: "I am excited to join the Topas team.

Brutons Tyrosine Kinase (BTK) Inhibitors Drug Pipeline Market Report 2022: Comprehensive Insights About 30+ Companies and 30+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期四, 二月 10, 2022
Health, Pharmaceutical, Mantle cell lymphoma, Chronic lymphocytic leukemia, Patient, Food, BTK, Pemphigus, Waldenström's macroglobulinemia, B-cell lymphoma, Shanda, Clinical trial, ITP, Bruton's tyrosine kinase, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Technology, FDA, Pemphigus foliaceus, Pemphigus vulgaris, Waldenström, European Commission, Acquisition, NDA, BeiGene, Lymphocytosis, Degenerative disease, Inhibitor, Discovery, News, Royal commission, II, Pharmaceutical industry

This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.

Key Points: 
  • This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
  • A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.
  • Brutons Tyrosine Kinase (BTK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Brutons Tyrosine Kinase (BTK) Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their Brutons Tyrosine Kinase (BTK) Inhibitors drug candidates in the most advanced stage, i.e.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
星期一, 二月 7, 2022
SLE, Drug discovery, Lupus, RA, Product life-cycle theory, Research, Multiple sclerosis, Company, Thirteenth, Ibrutinib, Asthma, IND, Rheumatoid arthritis, B-cell lymphoma, Program, NHL, CD22, BTK, Patient, Investigational New Drug, Safety, National Medical Products Administration, CDE, Mab, Center, Therapy, SM03, The Group, Pemphigus vulgaris, PV, NMPA, Twelfth, Center for Drug Evaluation and Research, The Company, Pharmaceutical industry, Phase

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of multiple sclerosis.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.